Reuters logo
Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial
November 28, 2017 / 1:16 PM / 17 days ago

Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial

FRANKFURT, Nov 28 (Reuters) - Germany’s Merck KGaA said on Tuesday that its cancer immunotherapy avelumab, jointly developed with Pfizer, failed to improve overall survival compared with standard chemotherapy in a late-stage study on gastric cancer patients. (Reporting by Ludwig Burger; Editing by Maria Sheahan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below